视网膜中央静脉阻塞后新生血管性青光眼的预测因素
该回顾性队列研究分析了2013至2017年间Bascom Palmer眼科研究所646例CRVO患者,其中98例符合纳入标准,13例(13%)发展为NVG。玻璃体腔抗VEGF治疗可延迟但未能预防NVG。
要点
- CRVO后NVG发生率为13%,平均诊断时间距症状出现212天。
- 系统性高血压病史、首发视力差和RAPD是NVG的独立危险因素。
- 抗VEGF治疗可延迟NVG发生但无法完全预防。
核心结论
- 系统性高血压病史、首发视力较差和RAPD是CRVO后发生NVG的危险因素。
- 具有这些表现的患者应密切随访并告知新生血管形成风险较高。
- 玻璃体腔抗VEGF治疗可延迟但未能预防NVG。
研究设计与样本
- 回顾性队列研究,纳入2013至2017年Bascom Palmer眼科研究所646例CRVO患者。
- 纳入标准:CRVO发病至就诊<90天、就诊时无前节新生血管、就诊前无玻璃体腔抗VEGF注射史。
- 符合纳入标准的98例患者接受NVG危险因素筛查,采用Kaplan-Meier生存分析和Cox比例风险模型评估风险。
主要发现
- 98例符合纳入标准的患者中13例(13%)发生NVG。
- 从CRVO相关症状出现至NVG诊断的平均调整时间为212天。
- 年龄、体重指数、青光眼病史、糖尿病史和中央视网膜厚度与NVG发展无显著关联。
关键数值与推荐
- NVG发生率:13/98(13%)。
- 从症状出现至NVG诊断的平均调整时间:212天。
临床怎么用
- 对CRVO患者应评估系统性高血压病史、首发视力和RAPD以识别NVG高危人群。
- 具有上述危险因素的患者应缩短随访间隔并告知新生血管形成风险。
- 抗VEGF治疗可延迟NVG发生,但不能替代密切监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the risk factors for development of neovascular glaucoma (NVG) in patients after an acute central retinal vein occlusion (CRVO). DESIGN: Retrospective cohort study. METHODS: Review of medical records of 646 patients with a diagnosis of CRVO between 2013 and 2017 at the Bascom Palmer Eye Institute. INCLUSION CRITERIA: (1) CRVO onset to presentation <90 days; (2) absence of anterior segment neovascularization on presentation; (3) no intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection before presentation. Patients meeting inclusion criteria were screened for potential risk factors for development of NVG. Risk of developing NVG was assessed with Kaplan-Meier survival analysis and Cox proportional hazards models. RESULTS: Thirteen of 98 patients (13%) who met inclusion criteria developed NVG. The mean adjusted time to NVG diagnosis from onset of CRVO-related symptoms was 212 days. Patients presenting with a worse initial visual acuity (P = .034), a relative afferent pupillary defect (RAPD) (P = .002), or a history of systemic hypertension (P = .026) had an increased risk of NVG compared to those who did not. Age, body mass index, history of glaucoma, history of diabetes, and central retinal thickness were not significantly associated with development of NVG. CONCLUSIONS: Risk factors for NVG development included history of systemic hypertension, worse visual acuity on presentation, and RAPD on presentation. Patients presenting with these findings should be followed at closer intervals and informed of the greater risk for neovascularization. Intravitreal anti-VEGF therapy delayed but did not prevent NVG.
引用
- Rong AJ, Swaminathan SS, Vanner EA, et al. Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. Am J Ophthalmol. 2019. PMID: 30862502. doi:10.1016/j.ajo.2019.02.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。